Business
Daré Bioscience Announces NIH Grant Award
Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing
About this update from Dare Bioscience, Inc.
[{"type":"text","content":"Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel designed to provide 6- or 12-month contraceptive protection SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) of the National Institutes of Health (NIH) of approximately $249,000 to support end-user research, including surveys of approximately 1,000 women in the U.S. ages 18-44 years, to better understand women’s preferences for a long-acting injectable (LAI) contraceptive method. The study will provide insights regarding duration preferences of users or potential users of LAI contraceptive products, how women evaluate LAI products against other contraceptive methods and the extent to which preferences will differ by age, socio-demographic characteristics, fertility intentions, reproductive history, and contraceptive history and general preferences. The findings of the study will also help to inform the characteristics of U.S. women most likely to be interested in using a LAI contraceptive method. “The grant will enable Daré to better understand women’s preferences, particularly with regard to the key features of LAI hormonal contraceptives,” said David Friend, PhD, Chief Scientific Officer of Daré Bioscience. “The findings from this study will inform our target product profile and guide our development priorities for ADARE-204 and ADARE-214. We are excited to be working with the Population Council on this important initiative and we are grateful to NICHD for its commitment to advancing new programs that have the potential to address unmet needs and offer a better experience for women.” This Notice of Award (Award Number R43HD108820) represents the third award that Daré has received from NICHD to inform or support the development of a contraceptive product candidate. Daré previously received grants from NICHD to support the development of DARE-LARC1, a long-acting, reversible personal contraceptive system in preclinical development, and Ovaprene®, an investigational hormone-free monthly contraceptive. About Long-acting Inject...